99mTc-imidodiphosphonate: a superior radio-pharmaceutical for in vivo positive myocardial infarct imaging. I: Experimental data.
99mTc-Imidodiphosphonate (99mTc-IDP) was investigated as an agent for nuclear medicine imaging of acute myocardial infarctions. For this purpose a suitable animal model was found. After coronary artery ligation reproducible myocardial infarcts were obtained with 80% of surviving animals. Scans of the myocardial infarcts were recorded with a high resolution gamma camera and good quality images were obtained. 99mTc-IDP ratios for normal and infarcted tissue were calculated and compared with similar data available from other 99mTc-labelled phosphates. With an infarct/normal ratio of 21:1, 99mTc-IDP is so far the best radiopharmaceutical for nuclear medicine imaging of necrosed heart muscle. Images of the myocardial infarcts have been recorded as early as 6 hours after infarction.
D000818:Animals; D004164:Diphosphonates / Q000378:metabolism; D006321:Heart / Q000000981:diagnostic imaging; D009203:Myocardial Infarction / Q000000981:diagnostic imaging* / Q000378:metabolism; D011877:Radionuclide Imaging; D051381:Rats; D013667:Technetium
D004164:Diphosphonates; C016514:imidodiphosphonic acid; D013667:Technetium